KLDO (Kaleido Biosciences) ROA %: -137.51% (As of Dec. 2021)


What is Kaleido Biosciences ROA %?

Kaleido Biosciences KLDO ROA % is -137.51% as of Dec. 2021.

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Kaleido Biosciences's annualized Net Income for the quarter that ended in Dec. 2021 was $-81.09 Mil. Kaleido Biosciences's average Total Assets over the quarter that ended in Dec. 2021 was $58.97 Mil. Therefore, Kaleido Biosciences's annualized ROA % for the quarter that ended in Dec. 2021 was -137.51%.

The historical rank and industry rank for Kaleido Biosciences's ROA % or its related term are showing as below:

KLDO's ROA % is not ranked *
in the Biotechnology industry.
Industry Median: -32.9
* Ranked among companies with meaningful ROA % only.

Kaleido Biosciences  (OTCPK:KLDO) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2021 )
=Net Income/Total Assets
=-81.088/58.9705
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-81.088 / 1.968)*(1.968 / 58.9705)
=Net Margin %*Asset Turnover
=-4120.33 %*0.0334
=-137.51 %

Note: The Net Income data used here is four times the quarterly (Dec. 2021) net income data. The Revenue data used here is four times the quarterly (Dec. 2021) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Kaleido Biosciences ROA % Related Terms


Kaleido Biosciences ROA % Historical Data

* Premium members only.

The historical data trend for Kaleido Biosciences's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kaleido Biosciences ROA % Chart

Kaleido Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
ROA %
Get a 7-Day Free Trial -154.23 -106.39 -103.00 -115.24 -164.94

Kaleido Biosciences Quarterly Data
Dec16 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -120.86 -112.15 -100.95 -121.42 -137.51

KLDO vs NPTX, GSTC, BZYR: ROA % Comparison

For the Biotechnology subindustry, Kaleido Biosciences's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kaleido Biosciences ROA % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kaleido Biosciences's ROA % distribution charts can be found below:

* The bar in red indicates where Kaleido Biosciences's ROA % falls into.



Kaleido Biosciences ROA % Calculation

Kaleido Biosciences's annualized ROA % for the fiscal year that ended in Dec. 2021 is calculated as:

ROA %=Net Income (A: Dec. 2021 )/( (Total Assets (A: Dec. 2020 )+Total Assets (A: Dec. 2021 ))/ count )
=-90.288/( (59.344+50.137)/ 2 )
=-90.288/54.7405
=-164.94 %

Kaleido Biosciences's annualized ROA % for the quarter that ended in Dec. 2021 is calculated as:

ROA %=Net Income (Q: Dec. 2021 )/( (Total Assets (Q: Sep. 2021 )+Total Assets (Q: Dec. 2021 ))/ count )
=-81.088/( (67.804+50.137)/ 2 )
=-81.088/58.9705
=-137.51 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2021) net income data. ROA % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROA % →
What does a ROA % of -137.51% mean?
Kaleido Biosciences (KLDO) has a ROA % of -137.51% as of Dec. 2021. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Kaleido Biosciences and its competitors.
Is Kaleido Biosciences' ROA % too high?
Kaleido Biosciences' current ROA % is -137.51%.
How does Kaleido Biosciences' ROA % compare to NPTX and GSTC?
Kaleido Biosciences' ROA % of -137.51% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Kaleido Biosciences and its competitors. Kaleido Biosciences's current ROA % is -137.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaleido Biosciences stock overvalued right now?
Kaleido Biosciences (KLDO) has a current ROA % of -137.51%. The current ROA % is -137.51%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Kaleido Biosciences (KLDO), the current ROA % is -137.51% as of Dec. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kaleido Biosciences Business Description

Address 65 Hayden Avenue, Lexington, MA, USA, 02421
Kaleido Biosciences Inc is a clinical-stage healthcare company. It is focused on leveraging the potential of the microbiome organ to treat disease and improve human health. Its product candidates are Microbiome Metabolic Therapies, or MMTs, which are designed to modulate the metabolic output and profile of the microbiome.